Extract
Exacerbations of chronic obstructive pulmonary disease (COPD) are acute events characterised by a worsening of respiratory symptoms that necessitates a change in medication and/or hospital admission [1]. Severe exacerbations (those resulting in hospitalisation and/or death) are associated with a poor prognosis [2], decreased quality of life [3] and higher mortality [2, 4]. Roflumilast is a once-daily, oral, selective phosphodiesterase-4 inhibitor that targets both the systemic and pulmonary inflammation associated with COPD [5]. Previous studies have shown that roflumilast as an add-on to inhaled therapies reduces COPD exacerbations in patients with severe COPD who have chronic bronchitis and a history of exacerbations [6–9]. However, the adverse events associated with systemic therapies such as roflumilast necessitate that these therapies are used to treat specific patient populations in whom they are likely to have the greatest clinical benefit [10].
Abstract
Roflumilast provides greater therapeutic benefit in severe COPD patients with a hospitalisation in the prior year http://ow.ly/lzWy30bNBd4
Acknowledgements
We thank Alexis Pashiardis (Synergy Vision, London, UK; supported by AstraZeneca) for writing and editorial assistance with the preparation of this research letter. These results were presented at the European Respiratory Society International Congress in 2015.
Footnotes
Clinical trial: This study is registered with clinicaltrials.gov with the identifier NCT01329029.
Support statement: This study was funded by Takeda Pharmaceutical Company and AstraZeneca. Funding information for this article has been deposited with the Crossref Funder Registry.
Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com
- Received January 23, 2017.
- Accepted March 29, 2017.
- Copyright ©ERS 2017
INDIVIDUALS
Log in using your username and password
PURCHASE SHORT TERM ACCESS
Purchase access - gain access to this article from US$15.00
Regain Access - You can regain access to a recently purchased content if the access period has not yet expired.
LIBRARY USERS
Log in through your institution
CONTACT US
If you have any questions about the ERS publications website, please contact info@ersj.org.uk